Bank of New York Mellon’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-34,241
| Closed | -$629K | – | 4395 |
|
|
2020
Q4 | $629K | Sell |
34,241
-1,907
| -5% | -$34.8K | ﹤0.01% | 3499 |
|
|
2020
Q3 | $663K | Sell |
36,148
-1,248
| -3% | -$21K | ﹤0.01% | 3346 |
|
|
2020
Q2 | $560K | Buy |
37,396
+1,767
| +5% | +$25.2K | ﹤0.01% | 3420 |
|
|
2020
Q1 | $563K | Buy |
35,629
+709
| +2% | +$11.5K | ﹤0.01% | 3301 |
|
|
2019
Q4 | $567K | Buy |
34,920
+2,196
| +7% | +$36.6K | ﹤0.01% | 3533 |
|
|
2019
Q3 | $486K | Sell |
32,724
-5,960
| -15% | -$80.3K | ﹤0.01% | 3551 |
|
|
2019
Q2 | $640K | Sell |
38,684
-275
| -0.7% | -$4.49K | ﹤0.01% | 3486 |
|
|
2019
Q1 | $674K | Buy |
38,959
+1,102
| +3% | +$20K | ﹤0.01% | 3403 |
|
|
2018
Q4 | $669K | Buy |
37,857
+5,308
| +16% | +$90.2K | ﹤0.01% | 3326 |
|
|
2018
Q3 | $591K | Sell |
32,549
-2,030
| -6% | -$41.6K | ﹤0.01% | 3555 |
|
|
2018
Q2 | $676K | Buy |
34,579
+23,354
| +208% | +$438K | ﹤0.01% | 3467 |
|
|
2018
Q1 | $197K | Buy |
+11,225
| New | +$205K | ﹤0.01% | 3935 |
|
|
2017
Q2 | – | Sell |
-40,268
| Closed | -$475K | – | 4373 |
|
|
2017
Q1 | $475K | Buy |
40,268
+762
| +2% | +$9.25K | ﹤0.01% | 3578 |
|
|
2016
Q4 | $517K | Buy |
39,506
+2,641
| +7% | +$35.4K | ﹤0.01% | 3580 |
|
|
2016
Q3 | $534K | Sell |
36,865
-848
| -2% | -$12K | ﹤0.01% | 3501 |
|
|
2016
Q2 | $453K | Buy |
37,713
+4,868
| +15% | +$78.2K | ﹤0.01% | 3585 |
|
|
2016
Q1 | $613K | Buy |
32,845
+290
| +0.9% | +$4.81K | ﹤0.01% | 3335 |
|
|
2015
Q4 | $699K | Hold |
32,555
| – | – | ﹤0.01% | 3376 |
|
|
2015
Q3 | $551K | Sell |
32,555
-2,342
| -7% | -$58.2K | ﹤0.01% | 3542 |
|
|
2015
Q2 | $1.31M | Buy |
34,897
+28,269
| +427% | +$912K | ﹤0.01% | 3185 |
|
|
2015
Q1 | $209K | Buy |
+6,628
| New | +$179K | ﹤0.01% | 3886 |
|
Bank of New York Mellon's CBMG Position: Q1 2021 in Review
Bank of New York Mellon sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 34,241 shares — an estimated $629K sold.
Bank of New York Mellon first reported a position in CBMG in Q1 2015 and held it in 21 quarters. The position peaked at $1.31M in Q2 2015. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Bank of New York Mellon reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Bank of New York Mellon sold 34,241 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $629K.
- Bank of New York Mellon first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 21 quarters.
- Bank of New York Mellon's Cellular Biomedicine Group, Inc. position peaked at $1.31M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Bank of New York Mellon's 13F filing for Q1 2021, filed 13 May 2021.